News & Videos - ARRAY BIOPHARMA INC. - English

...

Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer - As previously announced, BRAFTOVI combinations showed statistically significant improvement in OS and ORR versus control - - Data supports potential to be the first chemotherapy-free, targeted regimen for BRAF-mutant mCRC patients - - Results were presented in...

Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer PR Newswire BOULDER, Colo., June 25, 2019 BOULDER, Colo. , June 25, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present updated data from the combination of BRAFTOVI ® (encorafenib), a BRAF inhibitor, MEKTOVI ®...

URGENT ALERT: Monteverde & Associates PC Launches an Investigation Regarding the Following Merger PR Newswire NEW YORK, June 21, 2019 NEW YORK , June 21, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating: BioScrip, Inc. ( BIOS ) ("BioScrip") related to its merger agreement with HC Group Holdings II, Inc. ("Omega") and HC Group Holdings I, LLC...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition PR Newswire NEW YORK, June 18, 2019 NEW YORK , June 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (NASDAQ: ARRY) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE:PFE). Under the terms of the agreement, Array shareholders will receive $48...

Thinking about buying stock in Aurora Cannabis, Array Biopharma, Beyond Meat, Dare Bioscience, or Uniqure? PR Newswire NEW YORK, June 17, 2019 NEW YORK , June 17, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, ARRY, BYND, DARE, and QURE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ACB:...

Array BioPharma to Present at the Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference PR Newswire BOULDER, Colo., June 4, 2019 BOULDER, Colo. , June 4, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Operating Officer, Andrew Robbins , will speak at the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes, California . The public is welcome to participate in the conference through a webcast on the Array BioPharma website....

Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference PR Newswire BOULDER, Colo., May 29, 2019 BOULDER, Colo. , May 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Jefferies 2019 Global Healthcare Conference in New York City . The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: Jefferies 2019 Global Healthcare...

Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting - Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months - - Landmark analysis estimates 47% and 39% of patients alive at 3 and 4 years, respectively - - Oral poster presentation June 3, 2019 - PR Newswire BOULDER, Colo., May 29,...

Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer - BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control - - BRAFTOVI + MEKTOVI + cetuximab reduced the risk of death by 48% versus control - - Potential to be the first chemotherapy-free, targeted regimen for metastatic CRC patients - - Array intends...

Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire BOULDER, Colo., May 9, 2019 BOULDER, Colo. , May 9, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas . The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: Bank of America...

Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019 - Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter - - BEACON CRC Phase 3 trial interim analysis remains on track to report out this quarter - - BRAFTOVI in combination with MEKTOVI and an anti-EGFR antibody recommended by the National Comprehensive Cancer Network® (NCCN®) guidelines as a treatment option for patients with advanced...

Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019 PR Newswire BOULDER, Colo., April 30, 2019 BOULDER, Colo. , April 30, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, May 7, 2019 at 9:00 am ET . Date: Tuesday, May 7, 2019 Time: 9:00 a.m. Eastern Time Toll-Free: (844) 464-3927 Toll: (765) 507-2598 Pass Code:...

Array BioPharma to Present at the 39th Annual Cowen Health Care Conference PR Newswire BOULDER, Colo., March 5, 2019 BOULDER, Colo. , March 5, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 39 th Annual Cowen Health Care Conference in Boston . The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: 39 th Annual Cowen Health Care Conference Presenter:...

Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference PR Newswire BOULDER, Colo., Feb. 21, 2019 BOULDER, Colo. , Feb. 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the SVB Leerink Partners 8 th Annual Global Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: SVB Leerink...

Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019 - Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% - - Combination of BRAFTOVI, MEKTOVI and ERBITUX® (cetuximab) demonstrated 15.3 months median overall survival in safety lead-in of the Phase 3 BEACON CRC trial in BRAF-mutant metastatic colorectal cancer - - Cash, Cash Equivalents and Marketable...

Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019 PR Newswire BOULDER, Colo., Jan. 29, 2019 BOULDER, Colo. , Jan. 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, February 5, 2019 . Ron Squarer, Chief Executive Officer, will lead the call. Date: Tuesday, February 5, 2019 Time: 9:00 a.m. Eastern Time...

Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer - Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium - - Updated confirmed ORR remains 48% and updated median PFS remains 8.0 months - - Investor webcast will be held on Tuesday, January 15 at 9:00 AM ET - PR Newswire BOULDER, Colo., Jan. 14, 2019 BOULDER, Colo....

Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire BOULDER, Colo., Dec. 20, 2018 BOULDER, Colo. , Dec. 20, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco . The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: 37 th Annual J.P. Morgan Healthcare...

Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference PR Newswire BOULDER, Colo., Nov. 20, 2018 BOULDER, Colo. , Nov. 20, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 30 th Annual Piper Jaffray Healthcare Conference in New York . The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: 30 th Annual Piper Jaffray...